ArticleFrontiers in oncology2025
Shifting burden of nasopharyngeal carcinoma: global patterns and forecasts to 2050 from the GBD 2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The burden of nasopharyngeal carcinoma in countries of the Association of Southeast Asian Nations (ASEAN), 1990-2023: findings from the Global Burden of Disease Study 2023.Journal of cancer research and clinical oncology · 2026Article
- Quality and dissemination of nasopharyngeal cancer health information on TikTok and Bilibili: Cross-sectional study.Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nasopharyngeal carcinoma (NPC) exhibits pronounced geographical variation, with a high burden in specific regions. We assessed global, regional, and national trends in NPC burden from 1990 to 2021 and projected estimates to 2050. Methods: We analyzed data from the Global Burden of Disease (GBD) 2021 study for 204 countries and territories across 21 regions. Age-standardized incidence rate (ASIR), age-standardized death rate (ASDR), and age-standardized disability-adjusted life-years (DALYs) rate were estimated, and temporal trends were assessed using estimated annual percentage change (EAPC) by socio-demographic index (SDI), sex, and age group. Future burden from 2022 to 2050 was projected using a Bayesian age-period-cohort model. Results: In 2021, there were 118,878 incident cases, 75,359 deaths, and 2,490,191 DALYs due to NPC globally. The global ASIR was 1.38 per 100,000 population (EAPC -1.06), the ASDR was 0.87 (EAPC -2.17), and the age-standardized DALYs rate was 28.91 (EAPC -2.29). Incidence rate peaked at ages 65-69 years (4.23 per 100,000 population), with consistently higher rates in males than in females. East Asia had the highest regional ASIR, and Japan bore the highest age-specific disease burden. Projections indicate continued declines in apparent ASDR and DALYs rates globally to 2050, but rising ASIR in males, particularly in East Asia and high-middle SDI regions. Conclusions: Over the past three decades, global mortality and disability burden from NPC have decreased, whereas incidence has increased in selected populations. The projected rise in ASIR among males in high-risk regions highlights the need for targeted interventions, equitable resource allocation, and sustained surveillance to mitigate future burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.